Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clonotypic Diversity of the T-cell Receptor Corroborates the Immature Precursor Origin of Cutaneous T-cell Lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Estimating narrow-sense heritability using family data from admixed populations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: Investigation of signaling pathways altered by recurrent gene mutations and their clinical impact in a consecutive cohort of patients with newly diagnosed chronic lymphocytic leukemia (CLL). The heterogeneous clinical course and genetic complexity of CLL warrant improved molecular prognostication. However, the prognostic value of recurrent mutations at time of diagnosis remains unclear.

EXPERIMENTAL DESIGN: We sequenced samples from 314 consecutive, newly diagnosed patients with CLL to investigate the clinical impact of 56 recurrently mutated genes assessed by next-generation sequencing.

RESULTS: Mutations were identified in 70% of patients with enrichment among IGHV unmutated cases. With 6.5 years of follow-up, 15 mutated genes investigated at time of diagnosis demonstrated significant impact on time to first treatment (TTFT). Carrying driver mutations was associated with shorter TTFT and poor overall survival. For outcome from CLL diagnosis, the number of signaling pathways altered by driver mutations stratified patients better than the number of driver mutations. Moreover, we demonstrated gradual impact on TTFT with increasing number of altered pathways independent of CLL-IPI risk. Thus, a 25-gene, pathway-based biomarker assessing recurrent mutations refine prognostication in CLL; in particular for CLL-IPI low and intermediate risk patients. External validation emphasized that a broad gene panel including low burden mutations was key for the biomarker based on altered pathways.

CONCLUSIONS: We propose to include the number of pathways altered by driver mutations as a biomarker together with CLL-IPI in prospective studies of CLL from time of diagnosis for incorporation into clinical care and personalized follow-up and treatment.

OriginalsprogEngelsk
TidsskriftClinical Cancer Research
Vol/bind26
Udgave nummer6
Sider (fra-til)1507-1515
Antal sider9
ISSN1078-0432
DOI
StatusUdgivet - 15 mar. 2020

Bibliografisk note

Copyright ©2020, American Association for Cancer Research.

ID: 59005280